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Abstract 
Cancer is a prevalent concern in today’s society. It is the second most common death in 
the US, exceeded only by heart disease. Currently, cancer treatment options include surgery, 
radiation, chemotherapy, hormone therapy, biological therapy, targeted therapy and most recently 
immunotherapy. Within the past decade, there has been a huge upsurge in novel ideas and 
technology to combat this disease. From the 2000s, the Wiesner group has been working on 
silica-based nanomaterials for cancer “theranostics”, a combination of diagnostics with therapy. 
The first generation Cornell dots (CU dots) were fluorescent PEGylated silica nanoparticles used 
as targeted probes in cancer patient care. These particles have already received FDA-approval and 
have been tested in first-in-human clinical trials, making them the first inorganic-polymer hybrid 
diagnostic bio-probes to enter clinical trials. From these limited number of patient trials they can 
be injected in the body, flow through the bloodstream, and be excreted without noticeable side 
effects. The purpose of my research was to synthesize the next generation of particles, referred to 
as C’ dots, in aqueous solution thereby preventing volatile organic solvent waste, simplifying the 
synthesis process, and providing even brighter particles than before. Brighter particles allow for 
clearer visualization via higher signal to noise ratios in the body, which is especially beneficial 
when locating, imaging and excising a tumor. This is a valuable component of the particles as they 
enable more effective treatment of cancer cells, while allowing healthy, living cells to remain 
unharmed.  
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Introduction 
Cancer is a group of diseases characterized by uncontrolled growth and spread of abnormal 
cells. This can result in death if the spread is not detected and controlled. It is caused by both 
external factors and internal factors (Kawasaki, 2005). These include tobacco, infectious 
organisms, chemicals, radiation, inherited mutations, hormones, immune conditions, and 
mutations that occur from metabolism (Peto, 1983). Currently, cancer is typically treated with 
surgery, radiation, chemotherapy, hormone therapy, biological therapy, and targeted therapy 
(Schnipper, 2015). Cancer is a very prevalent concern in today’s society. About 1,685,210 new 
cancer cases were expected to be diagnosed in the U.S. in 2015. This year, about 595,690 
Americans are expected to die of cancer, which is more than 1,630 people a day. It is the second 
most common death in the U.S., exceeded only by heart disease. In the U.S., cancer accounts for 
nearly 1 of every 4 deaths (American Cancer Society, 2016). 
In science today, there have been many recent breakthroughs with nanotechnology, the 
engineering of functional systems at the molecular scale (Alexis, 2008). ‘Nanotechnology' refers 
to the ability to construct items from the bottom up, producing high performance products on the 
scale of nanometers (Harper, 2003). There is the possibility of utilizing them in detection, 
chemotherapy treatments, and initiating apoptosis of cancer cells through gene therapy, targeted 
gene delivery and gene transfer. Technology that will aid in the detection of cancerous cells, such 
as the creation of nanosensors, has been constructed at the molecular scale (Peng, 2010). As a 
promising platform, these materials are extremely sensitive, selective and responsive, and can be 
used to replace costly and tedious laboratory methods currently in use for monitoring a patient's 
blood for proteins, chemicals and pathogens (Nie, 2007).  
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Nanotechnology can also be used in sustained, controlled and targeted chemotherapy (or 
“personalized chemotherapy”), chemotherapy across various physiological drug barriers, such the 
gastrointestinal barrier for oral chemotherapy and the blood-brain barrier for treatment of brain 
tumors and other central nerve system diseases, and eventually, chemotherapy at home (Rahman, 
2012). Lastly, targeted gene delivery to selected cell types provides a means for highly specific 
gene expression. Improved efficiency of gene transfer could be achieved through enhancing the 
entry of gene vectors into the desired cells and reducing the uptake of the vectors by non-target 
cells (Labhasetwar, 2005).  
Many studies researching the utilization of nanotechnology in the field of oncology are 
currently ongoing. For example, in an article published in the Clinical Cancer Research journal, 
the researchers experimented with nanoparticles to be utilized as drug delivery systems. The 
objective of the nanoparticles was to kill cancer cells more effectively in order to reduce and 
overcome drug resistance. They also hypothesized how nanoparticles will be developed in the 
future to improve their therapeutic efficacy and functionality in future cancer treatments (Cho, 
2008). Nanoparticles can be made using a variety of materials including polymers, lipids, viruses, 
and organometallic compounds. For polymer-based drug carriers, the drug is either physically 
entrapped in or covalently bound to the polymer matrix (Peer, 2007). Polymeric micelles are based 
on amphiphilic block copolymers, which assemble to form a nano-sized shell structure in aqueous 
media. The hydrophobic core region collects the hydrophobic drugs and the hydrophilic shell 
region stabilizes the hydrophobic core and makes the polymers water-soluble, making the particle 
an appropriate candidate for administration (Nasongkla, 2006). The size of nanoparticles used in 
a drug delivery system should be large enough to prevent their rapid leakage into blood capillaries, 
but small enough to escape capture by fixed macrophages that are lodged in the reticuloendothelial 
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system. Having a hydrophilic surface also helps to evade macrophage capture (Khanna, 2012). 
Although numerous studies have already been conducted, the rate of translation of 
nanotechnologies, in particular nanoparticles, into clinical applications is still limited, leaving an 
abundant amount of future opportunities for exploration. 
From the 2000s, the Wiesner group at Cornell has been working on silica-based 
nanomaterials for cancer “theranostics” (Ow, 2005). The first generation of CU dots were FDA 
approved for first-in-human clinical trials in 2010, making them the first inorganic-polymer hybrid 
diagnostic bio-probe to enter clinical trials. Conducted at Memorial Sloan Kettering Cancer Center 
in NYC during 2011, these nanoparticles were injected in the body of a limited number of cancer 
patients, flowed through the bloodstream, passed through renal clearance, and were excreted 
within a couple of hours without noticeable side effects (Phillips, 2014).  
The purpose of the present study was to develop a new generation of CU dots, so called 
Cornell Prime dots (C’ dots), with better structure control, brighter fluorescence, higher synthesis 
purity and improved manufacture reliability. While original CU dots were synthesized in alcohol 
using the conventional Stöber process, the reaction solvent of C’ dots was switched from alcohol 
to water. This endows the synthesis system with high chemistry versatility. Based on this, new 
particle compositions have been explored. For example, by integrating aluminum into the silica 
nanoparticles, aluminum silicate C’ dots, so called AlC’ dots, were synthesized to further increase 
particle fluorescence brightness. Finally, efficient incorporation of highly negatively charged NIR 
emitting fluorophores was achieved.  
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Materials and Methods 
Materials 
Dimethyl sulfoxide (DMSO), isopropanol, (3-mercaptopropyl) trimethoxy-silane 
(MPTMS), tetramethyl orthosilicate (TMOS), tetraethyl orthosilicate (TEOS), aluminum-tri-sec-
butoxide (ASB), 2.0 M ammonia in ethanol and 27 wt % ammonium hydroxide were purchased 
from Sigma−Aldrich. 2-[methoxy (polyethyleneoxy)6-9propyl]trimethoxysilane (PEG-silane, 
molar mass of ∼500 g/mol) was purchased from Gelest. Cy5 and Cy5.5 florescent dyes were 
purchased from GE Healthcare Life Sciences. Deionized (DI) water was generated in the shared 
Nanobiotechnolgy Center (NBTC) lab using a Millipore Milli-Q system.  
Methods 
The following protocols were adapted from previous work in our lab. The C’ dot protocol 
follows the same steps as the CU dot protocol previously published, except for the synthesis of the 
silica precursors and the ability to add multiple silica shells while remaining under 10 nm (Ow, 
2005; Burns. 2009). 
Synthesis of sub-10 nm PEGylated silica nanoparticles 
This synthesis protocol spans 7 days. First, a mixture of 0.02 M NH3•H2O is made by 
combining 100 µL of 2.0 M ammonia aqueous solution with 10 mL of DI water in a small glass 
vial. The mixture is vortexed for 10 seconds and should be transparent. In a small, round bottom 
flask, 1 mL of this mixture is added to 9 mL of DI water. On a stir plate at room temperature, 0.43 
mmol of TMOS is added and left overnight. Next, 0.21 mmol of PEG-silane is added to the 
solution, while stirring overnight. Then, the flask is placed in a static, hot oil bath set at 80°C for 
24 hours. Next, the solution is cooled to room temperature and transferred to dialysis tubing (Pierce 
brand) with a 10,000 molecular weight cut-off (MWCO). The sample is set in a large 2000 mL 
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beaker filled with DI water. The water is changed once per day for 2 additional days to wash away 
any remaining reagents, such as free-floating PEG. After dialysis, the sample is removed from the 
tubing and filtered through a 0.2 µM syringe filter (Fisher brand) to remove aggregate particles or 
dust present in the solution. The protocol results in a 10 mL sample, containing blank core silica 
nanoparticles. Stored in a 20 mL glass vial at room temperature, the solution can undergo further 
characterization. 
Synthesis of sub-10 nm PEGylated fluorescent silica nanoparticles 
This synthesis protocol spans 8 days. First, Cy5 or Cy5.5 dye with maleimido functionality 
is conjugated to MPTMS in DMSO. The molar ratio of fluorophore to MPTMS is equal to 1:25. 
After 24 hours, this conjugated dye is added to the stirring solution of DI water, 0.02 M NH3•H2O, 
and TMOS. The protocol continues as previously described, with the addition of PEG-silane, heat 
treatment in a hot oil bath, dialysis and syringe filtering. This results in a 10 mL sample, containing 
fluorescent core silica nanoparticles. 
Synthesis of sub-10 nm PEGylated core-shell silica nanoparticles and sub-10 nm PEGylated 
fluorescent core-shell silica nanoparticles 
This synthesis protocol spans 10-11 days. Following the previously described protocols, 
core-shell nanoparticles can be synthesized with blank or fluorescent cores. After the mixture of 
DI water, 0.02 M NH3•H2O, and TMOS (with or without conjugated dye) is left stirring overnight, 
the solution is transferred to a large, round bottom flask and diluted by adding 40 mL of DI water. 
Then, 10 mL of this large batch is aliquoted into a small, round bottom flask and continues onto 
the PEGylation step. Addition of a single silica shell is achieved by dosing the stirring solution 
with a mixture of TEOS and DMSO, with a volume ratio of 1:4, using the Eppendorf Electronic 
Dispensing System. The system is set to dispense 10 µL every 15 minutes, eighty times. This step 
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is repeated until the desired layers of shells are added. In this case, we added up to 4 shells. To 
keep the pH at neutral for optimized reaction kinetics, ~2 mL of 0.02 M M NH3•H2O was added 
to the solution after the addition of 2 layers. This was monitored using color-changing pH paper. 
The protocol results in five, 10 mL samples, containing silica nanoparticles with 0, 1, 2, 3, or 4 
shells. 
Synthesis of sub-10 nm PEGylated aluminosilicate nanoparticles and sub-10 nm PEGylated 
fluorescent aluminosilicate nanoparticles 
This synthesis protocol spans 7-8 days. First, a mixture of 0.043 mmol of ASB is made in 
a small glass vial by dissolving a volume ratio of 1:9 ASB and isopropanol. In a small, round 
bottom flask, 9.6 mL of DI water is mixed with 400 µL of 0.5 M HCl. After stirring for 3 minutes, 
0.43 mmol of TMOS and the 0.043 mmol of ASB are added. Thirty minutes later, 0.21 mmol of 
PEG-silane is added and the solution is switched back to neutral pH by adding ~140 µL of 27 wt% 
ammonium hydroxide. The next day, the flask if transferred into a hot oil bath set at 80°C for 24 
hours. Similar to the previously described protocols, the solution is transferred to dialysis tubing 
with a 10,000 MWCO, the DI water is changed two additional times, and then the solution is 
filtered through a 0.2 µM syringe filter. This results in a 10 mL sample, containing blank or 
fluorescent core aluminosilicate nanoparticles.  
Synthesis of sub-10 nm PEGylated core-shell aluminosilicate nanoparticles and sub-10 nm 
PEGylated fluorescent core-shell aluminosilicate nanoparticles 
This synthesis protocol spans 10-11 days. Following the previously described protocols, a 
large batch of core-shell aluminosilicate nanoparticles can be synthesized with blank or fluorescent 
cores. Additional layers of silica are added to aliquots of the solution using the Eppendorf 
Electronic Dispensing System. After these additions, the synthesis continues as before. However, 
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0.21 mmol PEG with a molar mass of ~400 g/mol is added instead of PEG-silane. Then the pH is 
tuned back up to neutral, 0.21 mmol PEG-silane is added, heat treatment is applied, the solution is 
dialyzed and then syringe filtered. This results in five, 10 mL samples, containing aluminosilicate 
nanoparticles with 0, 1, 2, 3, or 4 shells. 
Characterization of particle morphology by dynamic light scattering 
Hydrodynamic particle sizes and size distributions were measured by dynamic light 
scattering (DLS), using a Malvern Zetasizer Nano-SZ. This machine is located in the NBTC lab 
in Duffield Hall. In a plastic cuvette, 1 mL of each sample was measured three times at 20 °C and 
the average diameter of each sample was calculated by averaging the mean diameters.  
Characterization of particle morphology by transmission electron microscopy 
To obtain transmission electron microscopy (TEM) images, the FEI Tecnai T12 Spirit 
microscope was operated at an acceleration voltage of 120 keV. This microscope is located on the 
first floor of Duffield Hall. 10 µL of silica nanoparticles, diluted 1:10 into absolute ethyl alcohol, 
were dropped onto a 150 mesh copper grid with carbon film backing, and dried in air.  
Characterization of fluorophore encapsulating particles by spectrophotometry 
Absorbance spectra of samples were measured by a Varian Cary Model 5000 
spectrophotometer. First, the concentrations of the samples were systematically varied, so that the 
absorbance spectra were matched. Since absorbance and optical density are directly related, 
matching the absorbance adjusted the optical density so they were the same for the different 
samples. Then, the absorbance-matched samples were subjected to emission scans using a Photon 
Technologies International Quantamaster spectrofluorometer. To calculate the quantum efficiency 
enhancement, the peak intensity of emission spectra of the particles was divided by the peak 
intensity of the absorption-matched solution of free dye. 
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Characterization of fluorophore encapsulating particles by fluorescence correlation spectroscopy 
Fluorescence correlation spectroscopy (FCS) was measured using a home-built FCS setup 
in the sub-basement of Bard Hall. A 633 nm solid-state laser was used as the laser source for the 
Cy5 and Cy5.5 fluorophores. From the FCS autocorrelation curves, the hydrodynamic size, 
brightness per particle, and particle concentration were obtained. Then, to calculate the number of 
fluorophores per particle, the particle concentration obtained from FCS was divided by the 
fluorophore concentration that was obtained from the absorbance measurements. 
Results and Discussion 
Controlled fluorescent core silica nanoparticle growth 
 Though the synthesis of these core silica nanoparticles was previously published by 
members of the Wiesner group, it was necessary for this researcher to be able to successfully 
reproduce the results before optimizing the protocol for silica shell additions. 
Figure 1 is an illustration of the composition of a C’ dot. As previously detailed in the 
Methods section, sub-10 nm diameter silica nanoparticles are synthesized in DI water at room 
temperature, with TMOS as the silica source and ammonium hydroxide as the base catalyst. After 
formation of the particles, particle growth is terminated with the addition of PEG-silane to the 
reaction. Heat treatment in a hot oil bath is followed by several days of dialysis and syringe filtering 
to clean the particles. These final two steps are necessary for removing unreacted reagents and 
aggregated particles.  
The synthesis protocol outlined is similar to the conventional Stöber method. The Stöber 
synthesis of colloidal silica was first described in 1968, and can yield monodisperse nano- to 
micro-meter sized silica nanoparticles. However, instead of alcohol as the reaction solvent, water 
was used. This lead to better-defined reaction kinetics for ultrasmall silica nanoparticle growth. 
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Although the hydrolysis rate of TMOS is greatly increased in water relative to alcohol, 
homogenous particles were still synthesized at high concentrations. This switch to water allows 
for the translation of these stable particles to biological applications by decreasing the exposure to 
toxic materials. Furthermore, termination of particle growth by PEG-silane addition provides 
another synthesis parameter by which particle size can be precisely controlled and final stability 
can be enhanced.  
 
 
 
 
 
 
 
 
 
Figure 1: Illustration of a C’ dot’s composition, which consists of a silica core and near IR Cy5 
fluorophores encapsulated in silica shells and covered in PEG chains and c(RGDyC) peptides 
 
Controlled fluorescent core-shell silica nanoparticle growth 
This section took up the majority of the time spent on this project. Optimization of the 
protocol for core-shell synthesis involved manipulating many variables. Some of these included 
the silica precursor used, the pH of the system, the concentration of the solution, the concentration 
of silica in each dose, the amount of doses per shell, and the amount of lag time between doses. 
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Figure 2 shows an illustration of the core-shell synthesis pathway. Deposition of additional 
silica shells was achieved by dosing the reaction with a mixture of TEOS and DMSO. The dosed 
silane would further condense onto the existing core particles after hydrolysis. This resulted in 
additional silica layers surrounding the cores.  
 
Figure 2: Illustration of the core-shell synthesis, which is water-based and yields blank or 
fluorescent silica nanoparticles after doping the solution with additional silica 
 
Initially, silica shell addition was attempted with TMOS. Early results indicated that simply 
dosing TMOS into the solution does not result in particle size increase. Shown in figure 3 is the 
DLS measurement of blank C’ dots with 2 shells, with an average size of ~3-4 nm. It is most likely 
that secondary nucleation, instead of condensation onto the existing particles, occurred due to the 
fast hydrolysis and condensation rates of TMOS in water. 
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Figure 3: DLS measurements of blank C’ dots with 2 TMOS shells. The Malvern Zetasizer 
recorded three measurements, each with 10 runs. The curves were superimposed and determined 
the particles were roughly 3-4 nm on average, which was inconsistent with the expected results. 
 
In order to overcome this challenge, TEOS was used instead of TMOS for silica shell 
addition. Structurally similar to TMOS, TEOS has a slower hydrolysis rate. After optimizing the 
conditions previously listed, the hydrolysis of TEOS was tuned to be slightly slower than the time 
required for a single dose to thoroughly mix with the entire solution. This allowed the TEOS dose 
to spread out into the solution, hydrolyze, and then condense onto the existing particles, instead of 
forming secondary particles.  
 
 
 
Blank core-shell silica nanoparticles were first synthesized using this protocol, resulting in 
a core size of ~ 4 nm. Three shells were added, giving particle sizes of 5.6 nm (1 shell), 6.5 nm (2 
shells), and 7.8 nm (3 shells). This was determined by TEM imaging, shown in figure 4, and 
confirmed by DLS measurements, shown in figure 5. After repeatable results were obtained 
successfully, the experiment was conducted with Cy5 dye-containing cores. 
3-4	nm 
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Figure 4: TEM images of blank silica nanoparticles with TEOS shells at two different 
magnifications (50 and 200 nm scale bars); (a) core, (b) 1 shell, (c) 2 shells, (d) 3 shells. An 
increase in diameter is observed as silica shells are added. In the images taken at a lesser 
magnification, the particles do not appear to be uniformly distributed. This apparent network 
pattern of particles is due to the sample preparation, resulting from capillary forces acting on the 
particles during water evaporation (images were obtained with the aid of Dr. Kai Ma). 
 
Figure 5: DLS measurements of C’ dot size; core = 4.1 nm, 1 shell = 5.6 nm, 2 shells = 6.5 nm, 3 
shells = 7.8 nm (images were obtained with the aid of Dr. Kai Ma). 
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Fluorescent particles allow for visualization when applied to cancer diagnostics. Figure 6 
shows the TEM images of these fluorescent C’ dots. By adding 1-4 silica shells to 5-nm-sized Cy5 
doped core particles, the diameter increases by <1 nm, which is the size of one single SiO2 unit in 
the particles. These data imply that the synthesis results in precise size control close to the atomic 
layer level.  
Figure 6: TEM images of Cy5-encapsulated fluorescent silica nanoparticles at two different 
magnifications, 50 nm and 200 nm; (a) core, (b) 1 shell, (c) 2 shells, (d) 3 shells, (e) 4 shells 
 
Figure 7 shows the absorbance and emission spectra of the core-shell silica nanoparticles, 
compared to free Cy5 dye. The varied sample concentrations were systematically diluted to the 
same concentration through matching their absorbance values. The emission from the absorbance 
matched samples increased when additional silica shell was added. Typically, the fluorescent cores 
have dye molecules not fully incorporated in the rigid network. When absorbing energy, some is 
transferred into interatomic forces, such as vibrations or bond rotations. As a result, the emitted 
energy is less than maximal. The observed increase in emission indicates that the extra silica layers 
enhance the quantum yield of the Cy5 dye through better encapsulation of the dyes inside the 
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particles. This increased brightness is desirable because it will allow more distinctive labeling with 
enhanced signal to noise ratios when imaging tumors in the body. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Absorbance-matched (left set of curves) and emission spectra (right set of curves with 
different peak heights) of core-shell silica nanoparticles measured by a spectrophotometer 
(measurements were obtained with the aid of Dr. Kai Ma). 
 
Figure 8 is an illustration of our home-built FCS setup. FCS, which stands for fluorescence 
correlation spectroscopy, is a correlation analysis of fluctuations of the fluorescence intensity. The 
technique is extremely useful when working with fluorescent nanoparticles. It can be used to 
measure several characteristics of the fluorescent probe in a single run. The autocorrelation 
function G(τ) is defined as:  
where F(t) is the fluorescence obtained from the volume at time t; τ is the delay, and δF(t) = F(t) - 
<F(t)> is the deviation from the mean fluorescence. Based on the calculation formula and the 
graphed values, the addition of silica shells results in a shift in the autocorrelation curves to the 
right, shown in figure 9. This tells us that there is slower diffusion, implying that the particles are 
increasing in size, which supports both the TEM and DLS data. 
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Figure 8: Illustration of the home-built FCS setup 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: FCS autocorrelation curves of core-shell silica nanoparticles (measurements were 
obtained with the aid of Dr. Kai Ma). 
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The FCS autocorrelation curves, G(τ), can tell us the number of diffusing species, N, based 
on the value of G(τ) at τ=0, which is proportional to 1/N, and the number of photons collected 
from the volume can tell us the average count rate per diffusing species. This in turn, allows 
determination of the number of dyes per particle (Figure 10) and brightness per particle. Figure 11 
suggests there is a quantum enhancement over free Cy5 dye, which increases from ~1.3 for the 
core particle to ~1.7 as the number of silica shells increases from 0 to 4. Quantum efficiency 
enhancement is determined from the difference of fluorescence intensity peak heights relative to 
free dye. Though there is no obvious trend in increased number of dyes per particle, enhancement 
of brightness per dye results in an increase of particle brightness.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Number of dye molecules per silica nanoparticle based on FCS measurements. Because 
these are relative measurements, the data point for Cy5 free dye is not 1.0. Systematic variation 
comes from the absorbance and emission measurements (measurements were obtained with the 
aid of Dr. Kai Ma). 
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Figure 11: Calculated fluorescence per particle is represented by the black dots. Measured 
fluorescence brightness per particle is represented by the columns. The disparity in calculated and 
measured fluorescence is a result of systematic error. The explanation for this disparity is 
unknown. Statistical error was not significant, evident from small error bars. (measurements were 
obtained with the aid of Dr. Kai Ma). 
 
Controlled fluorescent silica nanoparticle growth with different inorganic compositions 
The motivation for incorporating other inorganic compositions was the limitation of 
fluorophore incorporation with emission spectra further out into the Near Infrared (NIR) into our 
C’ dot silica nanoparticles. Typically, these fluorophores have larger molar mass and size, 
requiring more negatively charged sulfate groups on the periphery to generate water solubility. 
Since silica above its isoelectric point of pH > 2.7 is also negatively charged, strong electrostatic 
repulsive interactions make covalently encapsulating such highly negatively charged NIR 
fluorophores into silica nanoparticles challenging. 
Figure 12 is an illustration of the composition of an Al C’ dot. Shown in the Si-Al core is 
a model of the molecular structure of the aluminosilicate core. Shown in the model is an NIR Cy5.5 
dye covalently encapsulated in the network. As previously detailed in the Methods section, sub-
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10 nm diameter aluminosilicate nanoparticles are synthesized in DI water at room temperature, 
with ASB as the aluminum precursor, TMOS as the silica source and HCl as the acid catalyst. For 
the addition of silica shells, PEG chains of ~400 g/mol are first added, and then the pH of the 
solution is increased. After formation of the particles, particle growth is terminated with the 
addition of PEG-silane to the reaction. Heat treatment in a hot oil bath is followed by dialysis and 
syringe filtering to clean the particles, removing reaction reagents and aggregated particles. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Illustration of an Al C’ dot’s composition, which consists of an aluminosilicate core 
and near IR Cy5.5 fluorophores encapsulated in silica shells and covered in PEG chains and 
c(RGDyC) peptides 
 
First, blank core-shell aluminosilicate nanoparticles were synthesized using this protocol, 
resulting in a measured core size of ~ 3.5 nm by DLS. TEM imaging resulted in core size 
measurements of ~5 nm. Both of these are shown in figure 13. Once two shells were successfully 
added, the synthesis was repeated using Cy5.5 dye-containing cores. By adding 2 silica shells, the 
diameter increases by ~4 nm, which is shown in figure 14.  
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Figure 13: DLS measurement and TEM image of blank core aluminosilicate nanoparticles 
 
Figure 14: TEM images of aluminosilicate nanoparticles; (a) core, (b) 2 shells (images were 
obtained with the aid of Dr. Kai Ma). 
 
Once the conditions were optimized, the synthesis was applied to fluorescent particles. 
Figure 15 shows the absorbance and emission matched spectra of the core-shell aluminosilicate 
nanoparticles, compared to free Cy5.5 dye. Based on the graphs, the addition of shells significantly 
increased the quantum yield of Cy5.5 dye. Analysis of the data indicates that these dots have a 
quantum enhancement over free dye of 2.6, which is significantly larger than the 1.7 obtained for 
the core only.  
Additionally, the FCS autocorrelation curve shown in figure 16 implies that there is an 
increase in particle size, supporting both the TEM and DLS data. Similar to the reasoning for 
increased brightness due to increased rigidity of the core-shell silica nanoparticles, the 
incorporation of aluminum into the silica network also enhances its rigidity. Another contributing 
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factor may be a decrease in quenching, which is the loss of fluorescence signal due to short-range 
interactions between the fluorophore and the local environment, or between nearby fluorophores. 
The regular pattern of the aluminosilicate matrix with covalently linked dye, as well as 
encapsulation of the core, are two ways of ensuring optimized brightness per particle. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: Absorbance-matched (left set of curves) and emission spectra (right set of curves with 
different peak heights) of core-shell aluminosilicate nanoparticles measured by a spectrophoto-
meter (measurements were obtained with the aid of Dr. Kai Ma). 
 
 
 
 
 
 
 
 
 
 
Figure 16: FCS autocorrelation curves of core-shell aluminosilicate nanoparticles (measurements 
were obtained with the aid of Dr. Kai Ma). 
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Biological Implications and Future Work 
The research conducted by this author contributed to the development of ultrasmall, 
PEGylated, fluorescent core-shell silica nanoparticles. Compared to the original CU dot synthesis 
conducted with ethanol as the solvent, the C’ dot synthesis yields unprecedented control, especially 
below 10 nm. Controlled particle size and distribution is important for medical application. For 
example, sub-10 nm particles ensure effective renal clearance. These water-based nanoparticles 
have three important advantages: 
Firstly, synthesis in water is ideal if we want to commercialize this product in the future. 
Using water as the solvent is more environmentally friendly, especially if conducted on a large 
scale. Scaling up the batch size will require a significant amount of ethanol. Cost of manufacture 
is increased with the need to purchase these chemicals in bulk and dispose of hazardous waste 
materials. 
Secondly, producing water-based nanoparticles is more highly desired for the translation 
to clinical application. Because these materials are intended for nanomedicine, using ethanol as 
the solvent raises questions of possible toxicity when injected in the body. To decrease this 
possibility, the particles undergo extensive cleaning processes, which are also costly. Eliminating 
this issue results in decreased cost and safer materials. 
Lastly, the development of a water-based system opens the door to more versatile 
chemistry. In biology, reactions occur where water is the solvent. For example, diatoms, one of 
the most common type of phytoplankton, produce silica exoskeletons. Biosilica synthesis has 
become of increasing interest, especially in its application to chemical and pharmaceutical 
processes. Combined with this knowledge, our system has potential to be used for synthesizing all 
sorts of silica-based nanomaterials. 
	 26	
Additionally, fluorescence microscopy is usually the preferred method of choice for 
observing processes in living systems. Some of its advantages include its non-invasive utilization 
and sensitivity to subtle changes in biological processes. With the next generation of C’ dots being 
synthesized in water and to be even brighter particles than before, they hold a promising future for 
biological application and commercialization. These “ultrabright” and “ultrasmall” C’ dots are 
now being used in human clinical trials at Memorial Sloan Kettering Cancer Center, involving 
melanoma and brain cancer patients. The initial results are encouraging. Because C’ dots 
specifically target cancerous cells, they can serve as distinctive markers for surgeons during an 
operation. 
Through the work that has been conducted over the past couple of years, some limitations 
of these nanoparticles have already been encountered. The current project being pursued is the 
synthesis of other ultrasmall structures based on the non-traditional Stöber synthesis detailed here. 
Hopefully, these will result in nanoparticles that can serve as a robust cancer drug-delivering 
platform, with high specificity targeting cancerous cells. 
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